ASO Author Reflections: Survival for Stage III Melanoma—Where Do We Stand in the Current Landscape of Melanoma Therapies?

  • Yun SongEmail author
  • Giorgos C. Karakousis
ASO Author Reflections



Yun Song and Giorgos C. Karakousis report no conflict of interest.


  1. 1.
    Balch CM, Gershenwald JE, Soong S-J, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28(14):2452–9. Scholar
  2. 2.
    Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16. Scholar
  3. 3.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. Scholar
  4. 4.
    Song Y, Tieniber AD, Gimottty PA, et al. Survival outcomes of patients with clinical stage III melanoma in the era of novel systemic therapies. Ann Surg Oncol. 2019. Scholar
  5. 5.
    Eggermont AM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55. Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of SurgeryPerelman School of Medicine, University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations